Nextera AS, a drug and target discovery company built on the unique and novel NextCore protein engineering and discovery platform, announces a strategic collaboration with Zelluna Immunotherapy AS on optimizing T cell receptors (TCRs) for subsequent implementation...
News & Events
NextCore-generated state-of-the-art TCR-Like antibodies in celiac disease published in Science Immunology.
In a collaboration between researchers in Norway (Oslo University Hospital/University of Oslo and Nextera AS), USA (John Hopkins University) and Australia (Monash University), Nextera’s unique NextCore-Ab technology was employed to generate and characterize extremely sensitive TCR-Like antibodies towards gluten T cell epitopes. Their utility expand insight into celiac disease pathogenesis and opens the door for targeted therapeutic intervention
Oslo, Norway, 7. June, 2021 – Nextera AS, a drug and target discovery company built on a unique and novel phage display discovery platform, NextCore, announces the appointment of Dr. Bent Jakobsen to its Board of Directors.
Nextera’s CEO, Geir Åge Løset will give the presentation ” Combinatorial specificity profiling and engineering to safeguard and optimize TCR reactivity”
Nextera receives Norwegian Research Council funding to expand its NextCore platform with a novel therapeutic T cell receptor discovery pipeline.
Nextera is very pleased to announce that the Norwegian Research Council (NRC) has awarded a prestigious 15.7 MNOK grant funding to expand our NextCore platform with a novel discovery T cell receptor (TCR) discovery pipeline.
At the 12th annual PEGS Europe Summit, Nextera’s CEO GeirÅge Løset will present Nextera’s NextCore drug discovery platform.
This conference is the industry’s event for antibody and protein therapeutic science and technology in Europe. Nextera is in the forefront of such technology development.
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO International Convention June 8th – 12th. Book us for a digital meeting and we will present our unique NextCore Immunology platform.
Nextera’s unique pVII phage display technology expands insights into the biology of human FSAP haemostasis
In ChemBioChem we describe the employment of Nextera’s pVII peptide phage display technology in the fine-mapping of FSAP enzyme substrate specificity, which shows surprising new results.
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO Europe Spring Digital conference March 23rd – 25th.